The role of VISTA engagement in limiting neutrophil-mediated inflammation
The Journal of Immunology · 01.09.2025 · 214 (9) · 2385-2396
DOI: 10.1093/jimmun/vkaf132 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 26.06.2025. Verfasst von Elizabeth C Nowak und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Dartmouth Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, United States. Hauptthemen laut MEDLINE: Neutrophils, Inflammation, B7 Antigens, Arthritis, Experimental. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, NIAMS NIH HHS, Congressionally Directed Medical Research Programs Lupus Research Program.
Abstract (Originalsprache)
A growing body of evidence suggests that the immune checkpoint inhibitory receptor VISTA plays a central role in the regulation of innate immunity in the settings of inflammatory diseases and cancer. Neutrophils are among the cells that have the highest membrane density of surface VISTA. In this study, targeting VISTA on neutrophils with a monoclonal antibody resulted in a striking reduction in their lipopolysaccharide (LPS)- and chemokine-induced peripheral accumulation but did not reduce neutrophil levels at steady state. Fc receptor engagement and macrophages were required for the effects of anti-VISTA antibody on neutrophils. Concomitant with reduced peripheral neutrophil numbers, targeting VISTA increased neutrophil clearance by macrophages in the liver. In a murine model of neutrophil-mediated arthritis, anti-VISTA antibody treatment ameliorated disease severity, which was associated with reduced myeloperoxidase activity in the joints. These studies identify a novel therapeutic opportunity for targeting VISTA to control neutrophil-mediated inflammation and tissue injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Dartmouth Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, United States.
- Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, United States.
- ImmuNext Corporation, Lebanon, NH, United States.
- Department of Pediatrics, Division of Bone Marrow & Blood Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN, United States.
ORCID-Profile: Bruce R Blazar
Förderung
- NIAID NIH HHS
- NIAMS NIH HHS
- Congressionally Directed Medical Research Programs Lupus Research Program
- NIH
- NHLBI NIH HHS
- Dartmouth's Immune Monitoring and Flow Cytometry Resource
- National Cancer Institute Cancer
- NCI NIH HHS
Zitieren
APA
Nowak, E. C., Li, J., Peters, Z. T., Mendyka, L. K., ElTanbouly, M. A., Davis, W. L., Sergent, P., Lines, J. L., Smits, N. C., Mabaera, R., Rajanna, S., Carriere, C., Koehn, B., Allred, J., Blazar, B. R., Burns, C. M., Noelle, R. J., & Skopelja-Gardner, S. (2025). The role of VISTA engagement in limiting neutrophil-mediated inflammation. The Journal of Immunology, 214(9), 2385-2396. https://doi.org/10.1093/jimmun/vkaf132
Vancouver
Nowak EC, Li J, Peters ZT, Mendyka LK, ElTanbouly MA, Davis WL, et al. The role of VISTA engagement in limiting neutrophil-mediated inflammation. The Journal of Immunology. 2025;214(9):2385-2396. doi:10.1093/jimmun/vkaf132
BibTeX
@article{Nowak2025,
author = {Nowak, Elizabeth C and Li, Jiannan and Peters, Zachary T and Mendyka, Lindsay K and ElTanbouly, Mohamed A and Davis, Wilson L and Sergent, Petra and Lines, J Louise and Smits, Nicole C and Mabaera, Rodwell and Rajanna, Shibani and Carriere, Catherine and Koehn, Brent and Allred, Jeremy and Blazar, Bruce R and Burns, Christopher M and Noelle, Randolph J and Skopelja-Gardner, Sladjana},
title = {The role of VISTA engagement in limiting neutrophil-mediated inflammation},
journal = {The Journal of Immunology},
year = {2025},
volume = {214},
number = {9},
pages = {2385--2396},
doi = {10.1093/jimmun/vkaf132}
}
EUVIMED